Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
0.4950
+0.0358 (7.80%)
Jul 28, 2026, 2:42 PM EDT - Market open
Heron Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -30.94 | -20.2 | -13.58 | -110.56 | -182.02 | -220.68 |
Depreciation & Amortization | 2.29 | 2.31 | 2.49 | 2.9 | 2.89 | 3.02 |
Stock-Based Compensation | 10.8 | 10.34 | 12.96 | 32.85 | 42.98 | 46.85 |
Other Adjustments | -0.35 | 11.83 | 3.2 | -0.77 | -0.25 | 2.54 |
Change in Receivables | -4.96 | -10.71 | -18.74 | -8.09 | -16.55 | 6.35 |
Changes in Inventories | -27.45 | -31.05 | -11.05 | 12.46 | -6.19 | -6.48 |
Changes in Accounts Payable | -3.36 | -2.72 | 8.47 | 0.02 | -0.58 | 3.28 |
Changes in Accrued Expenses | 10.73 | 11.72 | 3.65 | -3.03 | 11.8 | -29.85 |
Changes in Other Operating Activities | 10.6 | 0.88 | -9.93 | 15.43 | 1.01 | -8.39 |
Operating Cash Flow | -20.26 | -27.59 | -22.53 | -58.79 | -146.91 | -203.35 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -0.6 | -0.32 | -1.71 | -1.55 | -1.83 | -3.02 |
Sale of Property, Plant & Equipment | 0.06 | 0.1 | 0.03 | 0.01 | 0.23 | 0.03 |
Purchases of Investments | -41.02 | -50.79 | -103.09 | -87.66 | -145.68 | -129.22 |
Proceeds from Sale of Investments | 54.36 | 67.01 | 123.48 | 107.19 | 143.96 | 164.94 |
Investing Cash Flow | 12.8 | 16.01 | 18.71 | 18 | -3.32 | 32.73 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | - | 137.25 | - | 24.35 | - | 148.96 |
Long-Term Debt Repaid | - | -150 | - | - | - | - |
Net Long-Term Debt Issued (Repaid) | - | -12.76 | - | 24.35 | - | 148.96 |
Issuance of Common Stock | 0.05 | 19.32 | 0.94 | 29.76 | 75.06 | 7.07 |
Net Common Stock Issued (Repurchased) | 0.05 | 19.32 | 0.94 | 29.76 | 75.06 | 7.07 |
Issuance of Preferred Stock | - | 7.86 | - | - | - | - |
Net Preferred Stock Issued (Repurchased) | - | 7.86 | - | - | - | - |
Financing Cash Flow | 14.31 | 14.43 | 0.94 | 54.11 | 75.06 | 156.03 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash Flow | 6.85 | 2.85 | -2.88 | 13.31 | -75.18 | -14.6 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -20.86 | -27.91 | -24.24 | -60.33 | -148.74 | -206.38 |
Free Cash Flow Growth | - | - | - | - | - | - |
FCF Margin | -13.84% | -18.02% | -16.80% | -47.49% | -138.14% | -239.01% |
Free Cash Flow Per Share | -0.12 | -0.17 | -0.16 | -0.44 | -1.37 | -2.10 |
Levered Free Cash Flow | -18.28 | -52.13 | -21.65 | -59.98 | -174.92 | -113.15 |
Unlevered Free Cash Flow | -18.24 | -21.72 | -19.6 | -84.38 | -167.55 | -259.26 |